Therini Bio, Inc.

Therini Bio, Inc.

A new approach to block vascular-mediated inflammation

Founded 2016

Sacramento, United States 15 employees Series A Total: $65.35M Biotechnology, Health Care +1

Therini Bio is a clinical-stage biotech company founded in 2016, with a focus on developing immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. By selectively targeting toxic fibrin accumulation, the company aims to tackle neuroinflammation in debilitating diseases such as Alzheimer’s disease (AD) and Diabetic Macular Edema (DME). The foundational science behind Therini Bio's work originated from technology discovered in Katerina Akassoglou’s, Ph.D., laboratories at the Gladstone Institutes at the University of California San Francisco (UCSF) and formerly the University of California San Diego (UCSD). The company has attracted substantial funding, with a $36.00M Series A investment announced on 27 April 2023. Notably, the top-tier syndicate of life sciences investors includes Alzheimer's Drug Discovery Foundation, SV Health Investors’ Biotech Fund, Dementia Discovery Fund, Dolby Family Ventures, Dreavent Biotech Investments, Eli Lilly and Company, Foundation for a Better World, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., and Sanofi Ventures. This investment reflects confidence in the potential of Therini Bio's approach and technologies to address unmet medical needs in the Biotechnology and Health Care industries. In summary, Therini Bio's innovative approach to developing immunotherapies for neuroinflammation, its strong foundation in scientific research, and the substantial backing from prominent investors position it as a compelling player in the biotech landscape, with the potential to make a significant impact in addressing diseases driven by vascular dysfunction.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	$36.00M	8	SV Health Investors, Dolby Ventures +6	27 Apr 2023
Grant	$3.00M	1	National Institutes of Health	01 Jan 2023
Seed Round	$17.00M	1	Foundation for a Better World	10 May 2021
Seed Round	$9.35M	-		08 Jul 2019

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

$36.00M

SV Health Investors, Dolby Ventures +6

27 Apr 2023

Grant

$3.00M

National Institutes of Health

01 Jan 2023

Seed Round

$17.00M

Foundation for a Better World

10 May 2021

Seed Round

$9.35M

08 Jul 2019

FAQ About Therini Bio, Inc.

A new approach to block vascular-mediated inflammation

Therini Bio, Inc. was founded in 2016.

Therini Bio, Inc. is headquartered in Sacramento, United States.

Therini Bio, Inc. operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Immunotherapy, Neuroinflammation, Vascular dysfunction and Biotech company.

Therini Bio, Inc. has approximately 15 employees.

Therini Bio, Inc. has completed 4 funding rounds, raising a total of $65.35M. The latest funding stage is Series A.

Top alternatives and competitors to Therini Bio, Inc. include AZTherapies, Allyx Therapeutics, VBL Therapeutics (Nasdaq:VBLT), Inflammx Therapeutics, Inc., 3T Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Therini Bio, Inc. and AZTherapies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Therini Bio, Inc.

Funding Rounds & Investors (4)

Therini Bio, Inc. Alternatives & Competitors

FAQ About Therini Bio, Inc.